Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | First Canadian Place 100 King Street West, Suite 4000 TORONTO ON M5X 1A4 |
Tel: | N/A |
Website: | https://www.fsdpharma.com |
IR: | See website |
Key People | ||
Anthony Durkacz Co-Chairman of the Board, Executive Director | Zeeshan Saeed Chief Executive Officer | Nathan Coyle Chief Financial Officer |
Donal Carroll Chief Operating Officer | Kevin Cassidy Vice President - Quality of Lucid | Andrzej Chruscinski Vice President - Clinical and Scientific Affairs |
Business Overview |
FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company's two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company's Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle. |
Financial Overview |
For the nine months ended 30 September 2023, FSD Pharma Inc revenues was not reported. Net loss before extraordinary items decreased 19% to $16.6M. Lower net loss reflects Gain on remeasurement of financial liabi increase from $120K to $4.9M (income), General and administrative decrease of 37% to $7.7M (expense), Depreciation and amortization decrease of 29% to $2.4M (expense). |
Employees: | 10 as of Dec 31, 2021 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $21.50M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$23.03M as of Dec 31, 2023 |
Net annual income (TTM): | -$25.09M as of Dec 31, 2023 |
Free cash flow (TTM): | -$14.90M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 40,429,641 as of Mar 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |